Business Wire

Parvus Therapeutics Announces Exclusive Worldwide License and Collaboration Agreement for the Development and Commercialization of Its Lead Nanomedicine to Treat Type 1 Diabetes

CALGARY, Alberta--(BUSINESS WIRE)--Parvus Therapeutics, a biopharmaceutical company developing disease-modifying nanomedicines to halt or reverse autoimmune disease without causing general immune ...
Business Wire

Parvus Therapeutics Appoints Dr. Curtis Ruegg as Chief Executive Officer

BURLINGAME, Calif.--(BUSINESS WIRE)--Parvus Therapeutics, a biopharmaceutical company developing disease-modifying nanomedicines to halt or reverse autoimmune disease without causing general immune ...
GEN

Genentech, Parvus Therapeutics Launch Up-to-$800M Autoimmune Collaboration

Genentech, a member of the Roche Group, today launched an up-to-$800 million partnership with Parvus Therapeutics to develop, manufacture, and commercialize new treatments for inflammatory bowel ...